TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.

Slides:



Advertisements
Similar presentations
A ggrastat- Phase of the AGGRASTAT to ZOCOR (A to Z) Trial Comparison of the safety and efficacy of unfractionated heparin versus enoxaparin in combination.
Advertisements

Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS) AHA, 2008.
Update on the Medical Management of Acute Coronary Syndrome.
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
VA NQWISH Veterans Affairs Non-Q Wave Infarction Strategies In-Hopsital Trial.
“Adjunctive Therapy” Non ST segment elevation ACS Dr M R Thomas King’s College Hospital. Advanced Angioplasty 2002.
Management of Acute Myocardial Infarction Minimal Acceptable vs Optimal Care Hussien H. Rizk, MD Cairo University.
Stanford ACS Guidelines 2003 David P. Lee, M.D. John S. Schroeder, M.D. *Donald Schreiber, M.D. Division of Cardiovascular Medicine and *Department of.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Optimal Management of ACS Invasive vs Conservative Strategy
Update on the Medical Management of Acute Coronary Syndrome.
Primary PCI Treatment of choice for Acute MI.
Download from Slide 1 AGGRASTAT ® † (tirofiban, MSD) to ZOCOR ™ † (simvastatin, MSD) (A to Z) Trial Results from the AGGRASTAT.
TACTICS-TIMI 18 Economics & HRQOL Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Amr Hassan Mostafa, MD, FSCAI A. Professor of Cardiology Cairo University Cairo, Egypt Egypt Combat MI, March 24-25, Cairo Sheraton.
Slide 1 AGGRASTAT ™ † (tirofiban, MSD) to ZOCOR ™ † (simvastatin, MSD) (A to Z) Trial Results from the AGGRASTAT Phase † Trademarks of Merck & Co., Inc.,
Intravenous GP IIb/IIIa Inhibitors Abciximab (c7E3 Fab, ReoPro) = Human- murine chimeric monoclonal Fab antibody fragment Eptifibatide (Integrilin) =
Clinical Trials of GP IIb/IIIa Inhibition Major Trials of GP IIb/IIIa Inhibitors in ACS GP IIb/IIIa Inhibitors in PCI GP IIb/IIIa Inhibition in Patients.
TIMI 11A A Multicenter Trial of the Safety and Tolerability of Two Doses of Enoxaparin in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction.
New Treatment Advances in Acute Coronary Syndrome.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Empiric Management of ACS With GP IIb/IIIa Platelet Receptor Blockers.
Incidence of Acute Coronary Syndromes (ACS): Statistics From Various Studies 1.4 million hospitalizations each year for ACS 944,000 hospitalizations for.
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
0009COR1 A CRUSADE to Improve Quality of Care for ACS Patients Eric D. Peterson, MD, MPH Associate Professor of Medicine Director of CV Outcomes and Quality.
“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
The Additive Value of Tirofiban Administered With the High-Dose Bolus in the Prevention of Ischemic Complications During High-Risk Coronary Angioplasty.
The INT egrelin and E noxaparin R andomized assessment of A cute C oronary syndrome Treatment T rial Sponsored by the Canadian Heart Research Centre, Key.
Acute Coronary Syndrome David Aymond, MD. ACS Definition: Myocardial ischemia typically due to atherosclerotic plaque rupture  Coronary thrombosis ACS.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
High-Dose, Double-Bolus Eptifibatide (Integrilin™) in Non- Urgent Coronary Stent Intervention 6 Month Results of the ESPRIT Trial.
Antiplatelet Interventions in Acute Coronary Syndromes.
(and r23-r35). A Phase 3 International, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
Cooling Off? Early Intervention? Very Early Intervention? Steve Holmberg Sussex Cardiac Centre.
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
GUSTO IV ACS: Trial Design Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: – ST  > 0.5 mm or – elevated.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
PROTECT: What Have We Learned Lesson 2: TMPG is associated with clinical and biomarker outcomes following PCI.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Annual Patient Admissions for Acute Coronary Syndromes 1.4 MM Non-ST elevation ACS 0.6 MM ST-elevation MI ~ 2.0 MM patients admitted to CCU or telemetry.
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.
Dr.Ali Eshraghi MD Interventional Cardiologist Non STE ACS  Angiographic Findings: 34% 3VD 28%2VD 26%SVD 10%LMCAD Culprit lesion charactristic: eccentric,scalloped,evidence.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: A guide to therapeutic decision-making in patients.
Occluded Artery Trial: 1° Hypothesis and Design 1° Hypothesis: Late PCI to open occluded IRA will ↓ death/reinfarction/class IV CHF by 25% compared to.
The Opus Trial. Antithrombotic Therapy Stable Angina Unstable Angina ST Elevation MI Non-Q wave MI Thrombolysis Non-ST Elevation MI Q wave MI.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Date of download: 7/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Small molecule glycoprotein IIb/IIIa receptor inhibitors.
The American College of Cardiology Presented by Dr. Adnan Kastrati
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Section F: Clinical guidelines
Section D: Clinical trial update: GP IIb/IIIa inhibition
Invasive versus conservative treatment in unstable coronary syndromes
TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI
The European Society of Cardiology Presented by RJ De Winter
American College of Cardiology Presented by Dr. Michel R. Le May
Clinical Trial Commentary
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.
Cardiovascular Epidemiology and Epidemiological Modelling
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy

Unstable Angina and Non-Q Wave MI Unstable Angina and Non-Q Wave MI è Center of spectrum of acute coronary syndromes è million hospital admissions /year worldwide è ASA, heparin, beta-blockers beneficial è Tirofiban (Aggrastat TM ) dramatic benefit è Invasive vs. Consvative strategy ???? Background

Unstable angina and non-Q wave MI è Center of spectrum of acute coronary syndromes è 890,000 hospital admissions per year in U.S. è ASA, heparin, beta-blockers beneficial è Tirofiban (Aggrastat TM ) dramatic benefit è Invasive vs. Consvative strategy ???? Background

l Initial Medical Management: l ASA mg daily for all patients with UA (except if ongoing major or life-threatening hemorrhage, recent GI bleed, or ASA hypersensitivity) l IV Heparin for intermediate or high-risk UA (i.e., prior CAD, rest pain, ECG changes, or age >65) l Beta-blockers for all patients in the absence of contraindications (e.g., bradycardia, hypotension, AV block, asthma, severe LV dysfunction with CHF or shock, signif. COPD) Recommendations AHCPR Unstable Angina Guideline Braunwald, E., et al. Circulation 1994;90:

l Initial Medical Management (con’t): l Nitrates: Use for patients with ongoing ischemia and use IV for high-risk patients. Switch to oral when stable l Calcium antagonists: May be used to control angina if already on beta-blocker and nitrates, or if unable to tolerate beta-blockers (e.g. severe COPD). Use heart-rate lowering Ca + blocker. Avoid in CHF or low EF. l No thrombolysis: Shown to increase subsequent MI in TIMI IIIB trial in patients with unstable angina Recommendations AHCPR Unstable Angina Guideline Braunwald, E., et al. Circulation 1994;90:

Cholesterol Lowering Post MI 4S CARE

l Cholesterol lowering: Check lipids 125 mg/dl. l Low Molecular Weight Heparin: At least as effective as IV heparin. ESSENCE trial: 16% better than IV heparin (Death, MI, recurrent angina) l IIb/IIIa inhibition: Tirofiban lead to a 34% reduction in death, MI, refarctory angina at 7 days in PRISM- PLUS. At 30 days, tirofiban (Aggrastat TM ) lead to a 31% redution in death or MI. In PRISM, there was a 36% reduction in composite endpoint at 48 hours. Eptifibatide (Integrilin TM ) lead to an 11% reduction in death or MI at 30 days in PURSUIT. Updating AHCPR Unstable Angina Guideline

l Early invasive strategy - Cath in all patients between hours. Revascularization when feasible based on anatomy: PTCA for 1 or 2 VD, CABG for 3VD l Early conservative strategy - catheterization if patient had recurrent ischemia at rest or on testing: l Recurrent ischemia at rest with ECG changes l Recurrent MI l Positive ETT / Thallium at HD or 6 weeks l Positive ST segment Holter (>20 mins) Invasive vs. Conservative TIMI IIIB Circulation 1994;89:

TIMI IIIB - One Year Results Death or MI PTCA or CABG P=<0.001 P=NS Anderson HV et al., JACC 1995;26: %10.8% 64%58% Early Conservative Early Invasive Early Conservative

TIMI IIIB - Primary Results to 42 days Invasive Conserv.P value Invasive Conserv.P value No. Pts Death (%) NS MI (%) NS D/MI/+ETT (%) NS Rehosp Angina (%) <0.001 D/MI/Rehosp (%) LOS (days) <0.001 # Days rehosp <0.001 Circulation 1994;89:

No. Pts Death or MI (%) Death (%) MI (%) Death < HD (%) Death > HD (%) Invasive Invasive Conserv. Conserv NS0.007NS P value P value VANQWISH Trial VA Hosptials Study: Management post Non-Q wave MI

l Medical and interventional magagement of unstable angina markedly improved in last 5 yrs ( ASA, heparin, stents, operator exper.) l Tirofiban improves: è Medical management of unstable angina (PRISM, PRISM-PLUS) è Outcome following PTCA (RESTORE) l With current optimal management Which is better and more cost-effective -> Invasive vs. Consvative strategy ? Study Rationale

TIMI IIIB: Troponin I vs. 42 Day Mortality 0-< < < < <9.0 > Death by 42 Days (%) cTnI at Baseline (ng/ml) Risk Ratio    p<0.001 Antman et al. NEJM 1996;335:

l Troponin T and I: associated with risk of death è TACTICS-TIMI 18 tests “Troponin Hypothesis” The troponins will be useful in determining the best treatment strategy (invasive vs. conservative) l Which is better - T or I? è TACTICS-TIMI 18 will be first large comparison Additional Objectives Troponin Hypothesis